DY
Therapeutic Areas
Maravai LifeSciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CleanCap® Technology Platform | mRNA Therapeutics & Vaccines | Commercial |
| TriLink Custom mRNA Manufacturing | Various genetic medicines | Commercial |
| Cygnus HCP Assay Platform | Biologics Safety Testing | Commercial |
| Modified Nucleotide Portfolio | Enhanced mRNA therapeutics | Research/Commercial |
| NTP Manufacturing | Nucleic acid synthesis | Commercial |
Leadership Team at Maravai LifeSciences
CW
Carl W. Hull
Chairman and Chief Executive Officer
KM
Kevin M. Herde
Chief Financial Officer
MJ
Michael J. Bannon
Chief Legal Officer and Corporate Secretary
TM
Trey Martin
President, Nucleic Acid Production
TD
Toby D. Wilson
President, Biologics Safety Testing
TJ
Tracy J. Krumme
Senior Vice President, Global Human Resources
MJ
Martin J. D. Allis
Director
JA
John A. Deford
Director
KO
Kurt O. Wood
Director
DB
David B. Singer
Director